معرفی
Aeson Chang is a Lecturer in the Drug Discovery Biology department at Monash University, where he conducts research at the intersection of pharmacology and cancer biology. His work is deeply rooted in understanding how the sympathetic nervous system influences breast cancer progression and metastasis.
His research interests center on breast cancer metastasis, drug repurposing for chemotherapy enhancement, and the role of biobehavioral and neuroimmune pathways in cancer outcomes. He investigates how beta-blockers can improve responses to anthracycline chemotherapy, particularly in aggressive triple-negative breast cancer, and how circadian disruption affects cancer-related inflammation.
The recent publications highlight a strong trend in translational oncology, combining preclinical models with epidemiological data to explore how commonly used drugs and lifestyle factors influence cancer progression. His work spans molecular pharmacology, systems physiology, and population health, aiming to bridge laboratory findings with clinical applications.
Dr. Chang has not been mentioned to have received any specific scientific awards in the provided text.
While there is no explicit mention of student supervision or grant funding in the provided content, his active collaboration with leading researchers such as Erica Sloan suggests involvement in funded research programs and mentorship within a team-based scientific environment.
His research is conducted within the Drug Discovery Biology theme at Monash University, a multidisciplinary environment focused on identifying novel therapeutic strategies for complex diseases including cancer.
